Clinical Trial

Treatment of Moderate to Severe Atopic Dermatitis

Study Description

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Upadacitinib (ABT-494)

Upadacitinib is administered orally

Drug - Dupilumab

Dupilumab is administered as a subcutaneous (SC) injection

Drug - Placebo

Placebo pre-filled syringe is administered as subcutaneous (SC) injections

Drug - Placebo

Placebo tablets are administered orally

Additional Information

Official Study Title

A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

Clinical Trial ID

NCT03738397

ParticipAid ID

bDkYna